FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220845808> ?p ?o ?g. }

• W4220845808 endingPage "154062" @default.
• W4220845808 startingPage "154062" @default.
• W4220845808 abstract "The current standard therapy for metastatic pancreatic cancer is ineffective, necessitating a new treatment approach for prognosis improvement. The urokinase-plasmin activator (uPA) is a critical factor in epithelial-mesenchymal transition (EMT) and cancer metastasis, but its underlying mechanisms in pancreatic cancer remains elusive.We investigated uPA expression in our pancreatic cancer cohort. A bioinformatics approach was used to further determine the role of uPA in pancreatic cancer. We employed MiaPaCa-2 and PANC-1 cell lines to investigate how uPA regulates EMT and metastasis in pancreatic cancer and present a novel approach aimed at inhibiting uPA in pancreatic cancer.We observed that higher uPA mRNA expression was significantly associated with overall-poor survival and progression-free survival in pancreatic cancer. uPA was highly expressed in tumor tissue. Gene set enrichment analysis revealed a positive association between uPA mRNA expression and EMT and transforming growth factor β (TGF-β) signaling pathways. Moreover, shRNA-mediated uPA gene knockdown reduced plasmin, MMP14, and TGF-β activation, leading to the inhibition of PANC-1 cells' EMT marker expression, migration, invasion, and cell viability. Notably, 4-acetyl-antroquinonol B (4-AAQB) treatment suppressed MiaPaCa-2 and PANC-1 cell migratory and invasive abilities by inhibiting the uPA/MMP14/TGF-β axis through upregulation of miR-181d-5p. In the xenograft mouse model of orthotropic pancreatic cancer, 4-AAQB treatment has reduced tumor growth and metastasis rate by deactivating uPA and improving the survival of the mice model.Accordingly, to extent of our knowledge and previous studies, we demonstrated that 4-AAQB is an anti Pan-Cancer drug, and may inhibit pancreatic cancer EMT and metastasis and serve as a new therapeutic approach for patients with late-stage pancreatic cancer." @default.
• W4220845808 created "2022-04-03" @default.
• W4220845808 creator A5013680967 @default.
• W4220845808 creator A5019857041 @default.
• W4220845808 creator A5024859729 @default.
• W4220845808 creator A5029957851 @default.
• W4220845808 creator A5034223519 @default.
• W4220845808 creator A5036593630 @default.
• W4220845808 creator A5055054595 @default.
• W4220845808 creator A5056734566 @default.
• W4220845808 creator A5076657463 @default.
• W4220845808 creator A5085961801 @default.
• W4220845808 creator A5089202859 @default.
• W4220845808 date "2022-06-01" @default.
• W4220845808 modified "2023-10-16" @default.
• W4220845808 title "Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP14/TGF-β axis, which is inhibited by 4-acetyl-antroquinonol B treatment" @default.
• W4220845808 cites W1078787812 @default.
• W4220845808 cites W2000241906 @default.
• W4220845808 cites W2011816149 @default.
• W4220845808 cites W2021808705 @default.
• W4220845808 cites W2091811255 @default.
• W4220845808 cites W2106505027 @default.
• W4220845808 cites W2126117802 @default.
• W4220845808 cites W2133968430 @default.
• W4220845808 cites W2149411663 @default.
• W4220845808 cites W2158089750 @default.
• W4220845808 cites W2298494136 @default.
• W4220845808 cites W2325967130 @default.
• W4220845808 cites W2508123382 @default.
• W4220845808 cites W2554987853 @default.
• W4220845808 cites W2586630468 @default.
• W4220845808 cites W2607413117 @default.
• W4220845808 cites W2774807260 @default.
• W4220845808 cites W2791482536 @default.
• W4220845808 cites W2805163386 @default.
• W4220845808 cites W2884985642 @default.
• W4220845808 cites W2917161013 @default.
• W4220845808 cites W2940057770 @default.
• W4220845808 cites W2979189134 @default.
• W4220845808 cites W2985049724 @default.
• W4220845808 cites W3136346673 @default.
• W4220845808 cites W3180345462 @default.
• W4220845808 doi "https://doi.org/10.1016/j.phymed.2022.154062" @default.
• W4220845808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35366491" @default.
• W4220845808 hasPublicationYear "2022" @default.
• W4220845808 type Work @default.
• W4220845808 citedByCount "6" @default.
• W4220845808 countsByYear W42208458082022 @default.
• W4220845808 countsByYear W42208458082023 @default.
• W4220845808 crossrefType "journal-article" @default.
• W4220845808 hasAuthorship W4220845808A5013680967 @default.
• W4220845808 hasAuthorship W4220845808A5019857041 @default.
• W4220845808 hasAuthorship W4220845808A5024859729 @default.
• W4220845808 hasAuthorship W4220845808A5029957851 @default.
• W4220845808 hasAuthorship W4220845808A5034223519 @default.
• W4220845808 hasAuthorship W4220845808A5036593630 @default.
• W4220845808 hasAuthorship W4220845808A5055054595 @default.
• W4220845808 hasAuthorship W4220845808A5056734566 @default.
• W4220845808 hasAuthorship W4220845808A5076657463 @default.
• W4220845808 hasAuthorship W4220845808A5085961801 @default.
• W4220845808 hasAuthorship W4220845808A5089202859 @default.
• W4220845808 hasConcept C104317684 @default.
• W4220845808 hasConcept C118131993 @default.
• W4220845808 hasConcept C121608353 @default.
• W4220845808 hasConcept C126322002 @default.
• W4220845808 hasConcept C127561419 @default.
• W4220845808 hasConcept C173396325 @default.
• W4220845808 hasConcept C181199279 @default.
• W4220845808 hasConcept C2779013556 @default.
• W4220845808 hasConcept C2779679481 @default.
• W4220845808 hasConcept C2780210213 @default.
• W4220845808 hasConcept C2781071845 @default.
• W4220845808 hasConcept C502942594 @default.
• W4220845808 hasConcept C54355233 @default.
• W4220845808 hasConcept C55493867 @default.
• W4220845808 hasConcept C56219504 @default.
• W4220845808 hasConcept C71924100 @default.
• W4220845808 hasConcept C76419328 @default.
• W4220845808 hasConcept C81885089 @default.
• W4220845808 hasConcept C86803240 @default.
• W4220845808 hasConcept C96232424 @default.
• W4220845808 hasConceptScore W4220845808C104317684 @default.
• W4220845808 hasConceptScore W4220845808C118131993 @default.
• W4220845808 hasConceptScore W4220845808C121608353 @default.
• W4220845808 hasConceptScore W4220845808C126322002 @default.
• W4220845808 hasConceptScore W4220845808C127561419 @default.
• W4220845808 hasConceptScore W4220845808C173396325 @default.
• W4220845808 hasConceptScore W4220845808C181199279 @default.
• W4220845808 hasConceptScore W4220845808C2779013556 @default.
• W4220845808 hasConceptScore W4220845808C2779679481 @default.
• W4220845808 hasConceptScore W4220845808C2780210213 @default.
• W4220845808 hasConceptScore W4220845808C2781071845 @default.
• W4220845808 hasConceptScore W4220845808C502942594 @default.
• W4220845808 hasConceptScore W4220845808C54355233 @default.
• W4220845808 hasConceptScore W4220845808C55493867 @default.
• W4220845808 hasConceptScore W4220845808C56219504 @default.
• W4220845808 hasConceptScore W4220845808C71924100 @default.
• W4220845808 hasConceptScore W4220845808C76419328 @default.

• next